Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An announcement from Nasus Pharma Ltd. ( (NSRX) ) is now available.
Nasus Pharma Ltd. announced the appointment of Eyal Rubin as Executive Vice President and Chief Financial Officer on November 19, 2025. Rubin, who brings over two decades of financial leadership experience, will oversee Nasus Pharma’s financial operations as the company advances its pipeline of intranasal therapeutics. This strategic appointment is expected to strengthen Nasus Pharma’s leadership team and support its growth as it progresses towards key clinical and commercial milestones.
The most recent analyst rating on (NSRX) stock is a Buy with a $22.00 price target. To see the full list of analyst forecasts on Nasus Pharma Ltd. stock, see the NSRX Stock Forecast page.
More about Nasus Pharma Ltd.
Nasus Pharma Ltd. is a clinical-stage pharmaceutical company focused on developing innovative intranasal products to treat emergency medical conditions. The company’s proprietary powder-based intranasal technology is designed for rapid and reliable drug delivery, offering a needle-free alternative for situations requiring quick absorption, such as anaphylaxis.
Average Trading Volume: 24,399
Find detailed analytics on NSRX stock on TipRanks’ Stock Analysis page.